Novartis eyes Rhapsido’s broader use on positive urticaria data drop

Novartis' Rhapsido (remibrutinib) showed positive results in a late-stage study for chronic induced urticaria (CIndU), potentially expanding its label. The drug demonstrated rapid and sustained symptom improvements across three CIndU subtypes. Novartis plans regulatory submissions for these new indications, aiming to increase Rhapsido's addressable patient population. Analysts expect Rhapsido to reach $5bn in sales by 2032, according to GlobalData.

Original reporting
Published Nov 13, 2026, 10:44 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 11:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$NVS
Bullish
high confidence
Mentioned
$NVS
Relevance
9/10
AlphAI data visualization · based on clinicaltrialsarena.com
Decision brief

The 30-second read

$NVSBullishHigh
01

Why it matters

The Phase III RemIND study shows durable responses across three chronic induced urticaria subtypes, supporting label expansion and significant revenue upside.

02

Market read

Positive trial data could drive a near‑term stock rally and long‑term valuation uplift for Novartis.

03

What to watch

Potential competition from other BTK inhibitors and reimbursement challenges.

Relevance 9/10Novelty 9/10Timing: today

Background

Novartis' Rhapsido is already approved for chronic spontaneous urticaria and symptomatic dermographism in the US.

Company-level read

Ticker impact

$NVSBullishHigh confidence
Context

Novartis reported positive Phase III data for Rhapsido in chronic induced urticaria, indicating potential label expansion.

Expected impact

likely upward pressure as investors price in expanded indication and sales potential

Evidence & confidence

Phase III data is a material catalyst; analysts expect the drug to become a blockbuster, which typically lifts the stock.

Market effects

strengthens the biotech/dermatology sector as a new label expansion opportunity.

beneficial for European and Asian markets where the drug is already approved.

adds a potential $5 bn revenue stream to Novartis, influencing global pharma valuations.

Counterpoint

If regulatory hurdles delay approval, the stock may not rally as expected.

Key entities

  • Novartis

    Swiss pharmaceutical giant developing Rhapsido.

  • Rhapsido (remibrutinib)

    BTK inhibitor being evaluated for chronic induced urticaria.

Related articles

$NVSMed

Novartis CEO Warns US-China Biotech Curbs

Novartis CEO Vas Narasimhan warned on Bloomberg TV that US-China biotech curbs could limit technology exchange, hindering R&D and market access. The Treasury Department proposed including biotech in investment limits for foreign adversaries, affecting multinational drugmakers like Novartis. Restrictions may slow drug development and access to key markets.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$NVSMedAI 8/10

Novartis Trims Growth Target at Annual Management Day, Shares Slide

Novartis reduced its mid-term sales growth outlook to 5% annually from 2026-2031, down from a prior 5-6% range. Shares fell 3% on the news. The revision follows patent expirations and clinical trial failures, including a $2.2B writedown. Despite this, Novartis raised peak sales forecasts for three key drugs: Kesimpta, Scemblix, and Leqvio. The company expects growth beyond 2031 from internally developed medicines, with 10 in late-stage development.

$NVSMed

Novartis trims medium-term growth target, shares fall

Novartis reduced its annual sales growth target to 5% through 2031, down from a previous range of 5%-6%. Shares fell 3.3% after the announcement, which came amid patent expirations and clinical trial setbacks. The company expects growth from existing drugs like Kesimpta, Scemblix, and Leqvio, with no large acquisitions planned. Analysts anticipate growth slowing post-2030 due to competition for key drugs.